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Summary  
  
Genetic influences on psychiatric disorders transcend diagnostic boundaries, 
suggesting substantial pleiotropy of contributing loci. However, the nature and 
mechanisms of these pleiotropic effects remain unclear. We performed a meta-analysis 
of 232,964 cases and 494,162 controls from genome-wide studies of anorexia nervosa, 
attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major 
depression, obsessive-compulsive disorder, schizophrenia, and Tourette syndrome. 
Genetic correlation analyses revealed a meaningful structure within the eight disorders 
identifying three groups of inter-related disorders. We detected 109 loci associated with 
at least two psychiatric disorders, including 23 loci with pleiotropic effects on four or 
more disorders and 11 loci with antagonistic effects on multiple disorders. The 
pleiotropic loci are located within genes that show heightened expression in the brain 
throughout the lifespan, beginning in the second trimester prenatally, and play 
prominent roles in a suite of neurodevelopmental processes. These findings have 
important implications for psychiatric nosology, drug development, and risk prediction. 
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INTRODUCTION 
  
Psychiatric disorders affect more than 25% of the population in any given year and are 
a leading cause of worldwide disability (Global Burden of Disease Injury Incidence 
Prevalence Collaborators, 2017; Kessler and Wang, 2008).  The substantial influence of 
genetic variation on risk for a broad range of psychiatric disorders has been established 
by both twin and, more recently, large-scale genomic studies (Smoller et al., 2018). 
Psychiatric disorders are highly polygenic, with a large proportion of heritability 
contributed by common variation. Many risk loci have emerged from genome-wide 
association studies (GWAS) of, among others, schizophrenia (SCZ), bipolar disorder 
(BIP), major depression (MD), and attention-deficit/hyperactivity disorder (ADHD) from 
the Psychiatric Genomics Consortium (PGC) and other efforts (Sullivan et al., 2018). 
These studies have revealed a surprising degree of genetic overlap among psychiatric 
disorders (Brainstorm Consortium, 2018; Cross-Disorder Group of the Psychiatric 
Genomics Consoritum, 2013). Elucidating the extent and biological significance of 
cross-disorder genetic influences has implications for psychiatric nosology, drug 
development, and risk prediction. In addition, characterizing the functional genomics of 
cross-phenotype genetic effects may reveal fundamental properties of pleiotropic loci 
that differentiate them from disorder-specific loci, and help identify targets for 
diagnostics and therapeutics.  
In 2013, analyses by the PGC’s Cross-Disorder Group identified loci with 
pleiotropic effects across five disorders: autism spectrum disorder (ASD), ADHD, SCZ, 
BIP, and MD in a sample comprising 33,332 cases and 27,888 controls (Cross-Disorder 
Group of the Psychiatric Genomics Consortium, 2013). In the current study, we 
examined pleiotropic effects in a greatly expanded dataset, encompassing 232,964 
cases and 494,162 controls, that included three additional psychiatric disorders: 
Tourette syndrome (TS), obsessive-compulsive disorder (OCD), and anorexia nervosa 
(AN). We address four major questions regarding the shared genetic basis of these 
eight disorders: 1) Can we identify a shared etiologic structure within the broad range of 
these clinically distinct psychiatric disorders? 2) Can we detect additional loci 
associated with risk for multiple disorders (pleiotropic loci)? 3) Do some of these risk loci 
have opposite allelic effects across disorders? and 4) Can we identify functional 
features of the pleiotropic loci that could account for their broad effects on 
psychopathology?  
  
 
RESULTS   
  
We analyzed genome-wide single nucleotide polymorphism (SNP) data for eight 
neuropsychiatric disorders using a combined sample of 232,964 cases and 494,162 
controls (Table 1; Supplementary Table 1). The eight disorders included AN (Duncan 
et al., 2017), ASD (Grove et al., 2017), ADHD (Demontis et al., 2019), BIP (Stahl et al., 
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2018), MD (Wray et al., 2018), OCD (International Obsessive Compulsive Disorder 
Foundation Genetics Collaborative (IOCDF-GC) and OCD Collaborative Genetics 
Association Studies (OCGAS), 2018), TS (Yu et al., In press.), and SCZ (Schizophrenia 
Working Group of the Psychiatric Genomics, 2014). All study participants were of self-
identified European ancestry, which was supported by principal component analysis of 
genome-wide data.   
 
Table 1. Summary of eight neuropsychiatric disorder datasets 
Disorder #Cases #Controls Total Samples 
# of 
GWAS 
Loci 
Population 
Prevalence 
(k) 
Liability-based 
SNP heritability 
(SE) 
References 
ADHD 19,099 34,194 53,293 9 0.05 0.222 (0.014) Demontis et al. 2019 
AN 3,495 10,983 14,478 0 0.01 0.195 (0.029) Duncan et al. 2017 
ASD 18,381 27,969 46,350 5 0.01 0.113 (0.010) Grove et al. 2017 
BIP 20,352 31,358 51,710 17 0.01 0.182 (0.011) Stahl et al. 2018 
MD 130,664 330,470 461,134 44 0.15 0.085 (0.004) Wray et al. 2018 
OCD 2,688 7,037 9,725 0 0.025 0.280 (0.041) IOCDF-GC and OCGAS 2018 
SCZ 33,640 43,456 77,096 108 0.01 0.222 (0.012) Schizophrenia Working Group of PGC. 2014 
TS 4,645 8,695 13,340 0 0.008 0.200 (0.026) Yu et al. 2018 
Total 232,964 494,162 727,126     
The number of cases and controls used in the meta-analysis of the present study. The numbers may 
differ from those reported in the original publications because our study included only European ancestry 
subjects to avoid potential confounding due to ancestral heterogeneity across distinct disorder studies. 
SNP heritability was estimated from the GWAS summary statistics using LD score regression. 
 
Genetic correlations among eight neuropsychiatric disorders indicate three 
genetic factors.  
After standardized and uniform quality control, additive logistic regression analyses 
were performed on individual disorders (Methods). A total of 6,786,994 SNPs were 
common across all datasets and were retained for further study. Using the summary 
statistics of these SNPs, we first estimated pairwise genetic correlations among the 
eight disorders using linkage disequilibrium (LD) score regression analyses (Bulik-
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Sullivan et al., 2015a) (Methods; Fig. 1a; Supplementary Table 2). The results were 
broadly concordant with previous estimates (Brainstorm Consortium, 2018; Cross-
Disorder Group of the Psychiatric Genomics Consoritum, 2013). The genetic correlation 
was highest between SCZ and BIP (rg = 0.70 ±0.02), followed by OCD and AN (rg = 
0.50 ±0.12). Interestingly, based on genome-wide genetic correlations, MD was closely 
correlated with ASD (rg=0.45 ±0.04) and ADHD (rg=0.44 ±0.03), two childhood-onset 
disorders. Despite variation in magnitude, significant genetic correlations were apparent 
for most pairs of disorders, suggesting a complex, higher-order genetic structure 
underlying psychopathology (Fig. 1b).   
  
We modeled the genome-wide joint architecture of the eight neuropsychiatric disorders 
using an exploratory factor analysis (EFA) (Gorsuch, 1988), followed by genomic 
structural equation modeling (SEM) (Grotzinger et al., 2018) (Methods). EFA identified 
three correlated factors, which together explained 51% of the genetic variation in the 
eight neuropsychiatric disorders (Supplementary Table 3). The first factor consisted 
primarily of disorders characterized by compulsive behaviors, specifically AN, OCD, 
and, more weakly, TS. The second factor was characterized by mood and psychotic 
disorders (MD, BIP, and SCZ), and the third factor by three early-onset 
neurodevelopmental disorders (ASD, ADHD, TS) as well as MD. Similar to our EFA 
results, hierarchical clustering analyses also identified three sub-groups among the 
eight disorders (Supplementary Fig. 1).   
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Figure 1. Genetic relationships between eight psychiatric disorders. A) SNP-based genetic 
correlations (rg) were estimated between eight neuropsychiatric disorders using LDSC. The size of the 
circles scales with the significance of the p-values. The darker the color, the larger the magnitude of rg. 
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Star sign (*) indicates statistical significance after Bonferroni correction. (B) SNP-based genetic 
correlations between eight disorders were depicted using an in-directed graph to reveal complex genetic 
relationships. Only significant genetic correlations after Bonferroni correction in (A) were displayed. Each 
node represents a disorder, with edges indicating the strength of the pairwise correlations. The width of 
the edges increases, while the length decreases, with the absolute values of rg.  (C) Based on results of 
an exploratory factor analysis of the genetic correlation matrix, a confirmatory factor model with three 
correlated genetic factors was specified using Genomic SEM and estimated with the weighted least 
squares algorithm. Two-headed arrows connecting the three factors to one another represent their 
correlations. Two-headed arrows connecting the genetic components of the individual psychiatric 
disorders to themselves represent residual genetic variances and correspond to the proportion of 
heritable variation in liability to each individual psychiatric disorder that is unexplained by the three 
factors. Standardized parameters are depicted with their standard errors in parentheses. Paths labeled 1 
with no standard errors reported are fixed parameters, which are used for scaling. 
 
 
Cross-disorder meta-analysis identifies 109 pleiotropic loci  
The factor structure described above is based on average effects across the genome, 
but does not address more fine-grained cross-disorder effects at the level of genomic 
regions or individual loci. To identify genetic loci with shared risk, we performed a meta-
analysis of the eight neuropsychiatric disorders using a fixed-effects-based method 
(Bhattacharjee et al., 2012) that accounts for the differences in sample sizes, existence 
of subset-specific effects, and overlapping subjects across datasets (Methods). There 
was no evidence of genomic inflation (λ1000 = 1.005; Fig. 2a). Using the primary fixed-
effects-based meta-analysis, we identified 136 LD-independent regions with genome-
wide significant association (Pmeta ≤ 5x10-8). Due to the known extensive LD at the major 
histocompatibility complex (MHC) region (chromosome 6 region at 25-35 Mb), we 
considered the multiple signals present there as one locus. 101 of the 136 (74.3%) 
significantly associated regions overlapped with previously reported genome-wide 
significant regions from at least one individual disorder, while 35 loci (25.7%) 
represented novel genome-wide significant associations.   
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Figure 2. Results of cross-disorder meta-analysis and candidate gene mapping. (A) Quantile-
quantile (QQ) plot displaying the observed meta-analysis statistics vs. the expected statistics under the 
null model of no associations in the -log10(p-value) scale. Although a marked departure is notable 
between the two statistics, the estimated lambda1000 and the estimated LD Score regression intercept 
indicate that the observed inflation is mainly due to polygenic signals rather than major confounding 
factors including population stratification. (B) Gene prioritization strategies for significantly associated loci. 
Candidate genes were mapped on each locus if the index SNP and credible SNPs reside within a protein-
coding gene, are eQTL markers of the gene in the brain tissue, or interact with promoter regions of the 
gene based on brain Hi-C data. (C) Manhattan plot displaying the cross-disorder meta-analysis results 
highlighting candidate genes mapped to top pleiotropic regions. 
 
Within these 136 loci, multi-SNP-based conditional analysis (Yang et al., 2012) 
identified 10 additional SNPs with independent associations, resulting in a total of 146 
independent lead SNPs (Supplementary Table 4). To provide a quantitative estimate 
of the best fit configuration of cross-disorder genotype-phenotype relationships, we 
estimated the posterior probability of association (referred to as the m-value) with each 
disorder using a Bayesian statistical framework (Han and Eskin, 2012) (Methods; 
Supplementary Table 5). As recommended, an m-value threshold of 0.9 was used to 
predict with high confidence that a particular SNP was associated with a given disorder. 
Also, m-values of < 0.1 were taken as strong evidence against association. Plots of the 
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SNP p-value vs. m-value for all 146 lead SNPs are shown in Supplementary Fig. 2. 
Nearly 75% (N = 109/146) of the genome-wide significant SNPs were pleiotropic (i.e., 
associated with more than one disorder). As expected, configurations of disease 
association reflected the differences in the statistical power and genetic correlations 
between the samples (Supplementary Fig. 3). Of the 109 pleiotropic loci, 83% and 
72% involved SCZ and BIP, respectively. MD, which had the largest case-control 
sample, was associated with 48% of the pleiotropic loci (N=52/109). Despite the 
relatively small sample size, ASD was implicated in 36% of the pleiotropic loci. Most of 
the ASD associations co-occurred with SCZ and BIP. The other disorders, ADHD, TS, 
OCD, and AN featured associations in 16%, 14%, 11%, and 7% of the pleiotropic loci, 
respectively. Of the single-disorder-specific loci, 81% and 16% were associated with 
SCZ and MD, respectively.  
  
Table 2 summarizes 23 pleiotropic loci associated with at least four of the disorders. 
Among these loci, heterogeneity of effect sizes was minimal (p-value of Q > 0.1). Eleven 
of the 23 regions map to the intron of a protein-coding gene, and seven additional lead 
SNPs had at least one protein-coding gene within 100 kb. We used an array of 
functional genomics resources, including brain eQTL and Hi-C data (Wang et al., 2018; 
Won et al., 2016) to prioritize potential candidate genes to the identified regions 
(Methods; Fig. 2b). The Manhattan plot in Fig. 2c highlights the prioritized candidate 
genes.   
Table 2. Summary of 23 loci with the broadest cross-disorder association 
SNP CHR BP Candidate Gene (evidence) ADHD ANO ASD BIP MD OCD SCZ TS m 
rs8084351 18 50726559 DCC(g,q) 0.961 0.905 0.97 0.965 1 0.951 1 0.984 8 
rs7193263 16 6315880 RBFOX1(g) 0.924 0.802 0.984 0.995 1 0.902 0.901 0.932 7 
rs12658451 5 103904037 - 0.963 0.165 0.999 0.972 1 0.574 1 0.963 6 
rs34215985 4 42047778 SLC30A9(g;q) 0.908 0.926 0.992 0.843 1 0.88 0.929 0.913 6 
rs61867293 10 106563924 SORCS3(g) 0.987 0.954 0.992 0.985 1 0.854 1 0.886 6 
rs9360557 6 73132745 KCNQ5(ha;hf) KCNQ5-IT1(hf) 0.905 0.938 0.976 0.984 0.993 0.897 1 0.892 6 
rs10149470 14 104017953 - 0.844 0.833 0.998 0.979 1 0.868 0.997 0.97 5 
rs11570190 11 57560452 CTNND1(g) OR5AK2(q) 0.927 0.79 0.97 0.58 1 0.916 1 0.832 5 
rs117956829 11 89339666 
TRIM64B(ha) 
GRM5(hf) 
TRIM77(hf) 
TYR(hf) 
0.723 0.929 0.972 0.906 1 0.66 0.997 0.789 5 
rs1484144 4 80217597 - 0.97 0.884 0.973 0.98 1 0.84 0.998 0.85 5 
rs6969410 7 110069015 - 0.836 0.827 0.987 0.93 0.999 0.917 1 0.729 5 
rs7531118 1 72837239 - 0.74 0.949 0.963 0.785 1 0.858 0.973 0.921 5 
rs9787523 10 106460460 SORCS3(g) 0.944 0.855 0.972 0.877 1 0.853 0.999 0.963 5 
rs10265001 7 140665521 - 0.716 0.772 0.986 0.999 0.783 0.921 0.988 0.692 4 
rs11688767 2 57988194 BCL11A(h) 0.845 0.899 0.929 0.983 1 0.849 1 0.698 4 
rs12129573 1 73768366 - 0.929 0.835 0.894 0.948 1 0.85 1 0.539 4 
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rs1518367 2 198807015 PLCL1(g) SF3B1(q) 0.897 0.783 0.913 0.991 1 0.674 1 0.865 4 
rs2332700 14 72417326 RGS6(g) 0.755 0.884 0.951 0.948 0.999 0.885 1 0.817 4 
rs5758265 22 41617897 L3MBTL2(g) CHADL(g) 0.735 0.885 0.89 0.885 1 0.913 1 0.978 4 
rs6125656 20 48090779 KCNB1(g) 0.768 0.885 0.986 0.995 0.985 0.731 0.999 0.707 4 
rs7405404 16 13749859 - 0.763 0.765 0.99 0.939 1 0.726 1 0.562 4 
rs78337797 12 23987925 SOX5(g) 0.849 0.797 0.97 0.954 1 0.831 0.996 0.885 4 
rs79879286 7 24826589 - 0.865 0.854 0.966 0.999 1 0.734 0.999 0.798 4 
SNP ID, location, prioritized candidate gene, disorder-specific m-values for 23 most pleiotropic loci. 
The number of disorders with high confidence association (m-values ≥0.9) is shown in the last 
column. Evidence for candidate gene mapping include: g (genic SNP); q (brain cis-eQTLs); h (hi-C 
interacting gene based on FUMA); hf (hi-C-based interaction between associated SNP and target 
gene in the fetal brain from Won et al. 2016); ha (hi-C-based interaction in the adult brain from Wang 
et al. 2018); and tss (transcription start sites).  
 
Of the 109 risk loci with shared effects, the 18q21.2 region surrounding SNP rs8084351 
at the netrin 1 receptor gene DCC featured the most pleiotropic association (Pmeta = 
4.26 x 10-12; Fig. 3a). This region showed association with all eight psychiatric 
disorders, and has been previously associated with both MD and neuroticism  
(Turley et al., 2018; Wray et al., 2018). The product of DCC plays a key role in guiding 
axonal growth during neurodevelopment and serves as a master regulator of midline 
crossing and white matter projections (Bendriem and Ross, 2017). Gene expression 
data indicate that DCC expression peaks during early prenatal development 
(Supplementary Fig. 4a).   
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Figure 3. Profile of disorder associations for illustrative pleiotropic loci: (A) rs8084351 on 18q21.2; 
(B) rs7193263 on 16p13.3; (C) rs117956829 on 11q14.3; and (D) rs10265001 on 7q34. For each 
locus, disorder-specific effects of the index SNP are shown using ForestPMPlot. The first panel is the 
forest plot, displaying disorder-specific association p-value, log odds ratios (ORs), and standard errors of 
the SNP. The meta-analysis p-value and the corresponding summary statistic are displayed on the top 
and the bottom of the forest plot, respectively. The second panel is the PM-plot in which X-axis 
represents the m-value, the posterior probability that the effect eixsts in each disorder, and the Y-axis 
represents the disorder-specific association p-value as -log10(p-value). Disorders are depicted as a dot 
whose size represents the sample size of individual GWAS. Disorders with estimated m-values of at least 
0.9 are colored in red, while those with m-values less than 0.9 are marked in green. 
 
The second most pleiotropic locus in our analysis was identified in an intron of RBFOX1 
(RNA Binding Fox-1 Homolog 1) on 16p13.3 (lead SNP rs7193263; Pmeta = 5.59 x 10-11). 
The lead SNP showed association with all of the disorders except AN (Fig. 3b). 
RBFOX1 (also called A2BP1) encodes a splicing regulator mainly expressed in neurons 
and known to target several genes important to neuronal development, including NMDA 
receptor 1 and voltage-gated calcium channels (Hamada et al., 2015). Knock-down and 
silencing of RBFOX1 during mouse corticogenesis impairs neuronal migration and 
synapse formation (Hamada et al., 2015; Hamada et al., 2016), implying its pivotal role 
in early cortical maturation. In contrast to DCC, however, developmental gene-
expression of RBFOX1 showed gradually increasing gene expression throughout the 
prenatal period (Supplementary Fig. 4b). Animal models and association studies have 
implicated RBFOX1 in aggressive behaviors, a trait observed in several of the disorders 
in our analysis (Fernandez-Castillo et al., 2017). 
  
Of the 109 pleiotropic loci, 76 were identified in the GWAS of individual disorders, while 
the remaining 33 are novel. The most pleiotropic among these novel loci was a region 
downstream of NOX4 (NADPH Oxidase 4) that was associated with SCZ, BIP, MD, 
ASD, and AN (rs117956829; Pmeta = 1.82 x 10-9; Fig. 3c). Brain Hi-C data (Wang et al., 
2018; Won et al., 2016) detected a direct interaction of the cross-disorder association 
region with NOX4 in both adult and fetal brain (interaction p=3.2x10-16 and 9.324x10-6, 
respectively). As a member of the family of NOX genes that encode subunits of NADPH 
oxidase, NOX4 is a major source of superoxide production in human brain and a 
promoter of neural stem cell growth (Kuroda et al., 2014; Topchiy et al., 2013). 
  
Figure 3d illustrates another novel psychiatric risk locus associated with SCZ, BIP, 
ASD, and OCD (Pmeta = 3.58 x 10-8). The lead SNP rs10265001 resides between 
MRPS33 (Mitochondrial Ribosomal Protein S33) and BRAF (B-Raf Proto-Oncogene, 
Serine/Threonine Kinase) on 7q34. The brain Hi-C data indicated interaction of the 
associated region with the promoters of two nearby genes: BRAF, which contributes to 
the MAP kinase signal transduction pathway and plays a role in postsynaptic responses 
of hippocampal neurons (Grantyn and Grantyn, 1973), and KDM7A (encoding Lysine 
Demethylase 7A), which plays a central role in the nervous system and midbrain 
development (Horton et al., 2010; Qi et al., 2010; Tsukada et al., 2010).      
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Our prior cross-disorder meta-analysis of five psychiatric disorders(Cross-Disorder 
Group of the Psychiatric Genomics Consortium, 2013) found no evidence of SNPs with 
antagonistic effects on two or more disorders. Here, we examined whether any variants 
with meta-analysis p ≤ 1x10-6 had opposite directional effects between disorders 
(Methods). After adjusting for having examined 206 loci across eight disorders (q < 
0.001), we identified 11 loci with evidence of opposite directional effects on two or more 
disorders (Fig. 4; Supplementary Table. 6). The disorder configuration of opposite 
directional effects varied for the 11 loci, including three loci with opposite directional 
effects on SCZ and MD (rs301805, rs1933802, rs3806843), two loci between SCZ and 
ASD (rs9329221, rs2921036), and one locus (rs75595651) with opposite directional 
effects on the two mood disorders, BIP and MD. Notably, all of the six loci involving SCZ 
and BIP exhibited the same directional effect on the two disorders (Pbinom < 0.05), in line 
with their strong genome-wide genetic correlation.    
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Figure 4. Eleven loci with opposite directional effects. The radius of each wedge corresponds to the 
absolute values of the Z-scores (log(Odds ratios)/S.E) obtained from association tests of the SNP for 
eight disorders. The color indicates whether the examined SNP carries risk (red) or protective effects 
(green) for each disorder. The dotted line around the center indicates statistically significant SNP effects 
that account for multiple testing of 206 SNPs with the q-value of 0.001.     
 
Functional characterization of pleiotropic risk loci   
  
We conducted a series of bioinformatic analyses that examined whether loci with 
shared risk effects on multiple neuropsychiatric disorders had characteristic features 
that distinguished them from non-pleiotropic risk loci. First, we annotated the functional 
characteristics of 146 lead SNPs using various public data sources (Methods; 
Supplementary Table 7-9). Overall, they showed significant enrichment of genes 
expressed in the brain (beta=0.123, SE=0.0109, enrichment p = 1.22x10-29) and 
pituitary (beta=0.0916, SE=0.0136, p = 8.74 x 10-12), but not in the other Genotype-
Tissue Expression (GTEx) tissues. (Supplementary Table 10; Fig. 5a). A separate 
analysis of 109 pleiotropic risk loci also showed specific enrichment of genes expressed 
in multiple brain tissues (p = 1.55 x 10-5; Supplementary Table 11), while disorder-
specific loci showed nominally enriched brain gene expression in the cortex (p =2.14 x 
10-2; Supplementary Table 12).   
 
Gene-set enrichment analyses using Gene Ontology data suggested involvement of 
pleiotropic risk loci in neurodevelopmental processes (Supplementary Table 13,14). 
The 109 pleiotropic risk loci were enriched for genes involved in neurogenesis (gene-set 
enrichment p = 9.67 x 10-6), regulation of nervous system development (p = 3.41 x 10-5), 
and neuron differentiation (p = 3.30 x 10-5), while enrichment of these gene-sets was not 
seen for disorder-specific risk loci (adjusted enrichment p > 0.05). Pleiotropic risk loci 
also showed enrichment of genes involved in specific neurotransmitter-related pathways 
-- glutamate receptor signaling (p = 2.45 x 10-6) and voltage-gated calcium channel 
complex (p = 5.72 x 10-4) -- while non-pleiotropic risk loci, which were predominantly 
SCZ-associated, were over-represented among acetylcholine receptor genes (p = 7.25 
x 10-8). Analysis of cortical gene expression data also suggested enrichment of 
pleiotropic risk genes in cortical glutamatergic neurons through layers 2-6 
(Supplementary Table 15), further supporting the shared role of glutamate receptor 
signaling in the pathogenesis of diverse neuropsychiatric disorders.  
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Figure 5. Results of functional genomics data analysis for pleiotropic vs. disorder-specific loci. (A) 
GTEX tissue-specific enrichment results for 146 risk loci associated with at least one of eight 
neuropsychiatric disorders. GTEX tissues were classified as 9 distinct categories, of which the brain 
tissues were colored in blue. The dotted red line indicates a statistically significant p-value after 
conducting Bonferroni correction for multiple testing. Psychiatric disorder-associated loci show significant 
enrichment in genes expressed in pituitary and all brain tissues except nerve_tibal. (B) Brain 
developmental expression trajectory displayed for the three groups of genes based on Kang et al. The 
146 genome-wide significant loci from the cross-disorder meta analysis were clustered into three groups 
based on predicted disorder-specific associations: (1) no-pleiotopy; (2) pleiotropy=2; and (3) pleiotropy>2. 
The “no-pleiotropy” group included 37 loci that showed a single-disorder-specific association, while the 
“pleiotropy=2” and “pleiotropy>2” groups included 60 and 49 loci that were associated with two and more 
than two disorders, respectively. (C) In the adult cortex, genes mapped to pleiotropic loci were enriched 
for frontal cortex specific genes, while genes mapped to non-pleiotropic loci are enriched for occipical 
cortex specific genes. (D) Genes mapped to 146 risk loci show higher expression values in neurons and 
oligodendrocytes, with much higher neuronal specificity for pleiotropic loci. 
  
In contrast to the differences in neuronal development and neuronal signaling pathways, 
pleiotropic and non-pleiotropic risk loci shared several characteristics related to genomic 
function. For instance, gene-set enrichment analyses indicated that both pleiotropic and 
non-pleiotropic risk loci were enriched for genes involved in the regulation of synaptic 
plasticity, neurotransmission, and synaptic cellular components.  More than 41% of the 
genes associated with our genome-wide significant loci, both pleiotropic and non-
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pleiotropic, were intolerant of loss of function mutations (pLI score ≥ 0.9); this is highly 
unlikely to occur by chance (Fisher’s exact p=4.90x10-8). This finding was consistent 
when examining pleiotropic (p=2.85x10-11) and non-pleiotropic risk loci (p=1.56x10-3) 
separately.        
 
Next, we compared spatio-temporal gene-expression patterns for the 109 pleiotropic 
risk loci and the 37 disorder-specific loci using post-mortem brain data. On average, 
disorder-specific and pleiotropic risk loci showed a similar level of gene expression in 
both prenatal and postnatal development after multiple testing correction (t-test p > 
0.025 x10-2; Supplementary Fig. 5). During prenatal development, non-pleiotropic loci 
(mainly SCZ-associated) showed peak expression in the first trimester, after which 
expression rapidly decreased, while pleiotropic genes associated with only 2 disorders 
(“pleiotropy=2”; 60 loci) and those associated with more than 2 (“pleiotropy>2”, 49 loci) 
showed peak expression around the second trimester (Fig. 5b). After birth, all three 
groups showed gradually increasing gene expression until adulthood. Expression levels 
were associated with the degree of pleiotropy, with the pleiotropy>2 group showing 
higher gene expression than either the pleiotropy=2 group (t-test p < 2.10x10-4) or non-
pleiotropic risk loci (t-test p < 2.2x10-16).      
  
Enrichment analyses using the genes preferentially expressed in specific cortical 
regions suggested that pleiotropic loci were over-represented among genes expressed 
in the frontal cortex, while non-pleiotropic loci were enriched in the occipital cortex (FDR 
q<0.05; Fig. 5c). Cell-type-specific analysis indicated that genes implicated in 
pleiotropic loci were mainly expressed in neurons (FDR q<0.05) but not in glial cell 
types. Further, enrichment of pleiotropic loci in neuronal cells was also associated with 
the degree of pleiotropy, as highlighted in Fig. 5d.   
  
Previous studies of model organisms using gene knock-out experiments suggested that 
pleiotropic risk loci may undergo stronger selection than non-pleiotropic loci (Hill and 
Zhang, 2012). However, we found no evidence that pleiotropic risk variants are under 
stronger evolutionary constraints (Supplementary Table 16). Various comparative 
genomics resources, including PhyloP (Pollard et al., 2010), PhastCons (Siepel et al., 
2005), and GERP++ (Davydov et al., 2010), showed our top loci to have similar 
properties regardless of the extent of pleiotropy. Neither did we find differences between 
disorder-specific lead SNPs and pleiotropic SNPs with respect to their minor allele 
frequencies, average heterozygosity, or predicted allele ages (Kiezun et al., 2013). 
Pleiotropic and non-pleiotropic SNPs also did not differ in terms of the distance to 
nearest genes, distance to splicing sites, chromosome compositions, and predicted 
functional consequences of non-coding regulatory elements.   
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Relationship between cross-disorder genetic risk and other brain-related traits 
and diseases   
To explore the genetic relationship of cross-disorder genetic risk with other traits, we 
treated this 8-disorder GWAS meta-analysis as a single “cross-disorder phenotype.” We 
applied LDSC to estimate SNP heritability (h2SNP) and genetic correlations with other 
phenotypes, using block jackknife-based standard errors to estimate statistical 
significance. The estimated h2SNP of the cross-disorder phenotype was 0.146 (SE 
0.0058; observed scale). Using data for 28 brain-related traits selected from LDHub 
(Zheng et al., 2017), we found significant genetic correlations of the cross-disorder 
phenotype with seven traits (at a Bonferroni-corrected p-value threshold 0.002): 
never/ever smoking status, years of education, neuroticism, subjective well-being, and 
three sleep-related phenotypes (chronotype, insomnia, and excessive daytime 
sleepiness) (Supplementary Table 17).  
  
GWAS catalog data for the 109 pleiotropic risk loci showed enrichment of implicated 
genes in a range of brain-related traits (Supplementary Table 18). As expected, the 
associated traits included previous studies of neuropsychiatric disorders including SCZ, 
BIP, and ASD. In addition, the pleiotropic risk loci were enriched among genes 
previously associated with neuroticism (corrected enrichment p= 5.28x10-6; GRIK3, 
CTNND1, DRD2, RGS6, RBFOX1, ZNF804A, L3MBTL2, CHADL, RANGAP1, RSRC1, 
GRM3), cognitive ability (corrected p= 7.15x10-5; PTPRF, NEGR1, ELOVL3, SORCS3, 
DCC, CACNA1I), and night sleep phenotypes (corrected p= 1.86x10-2; PBX1, NPAS3, 
RGS6, GRIN2A, MYO18A, TIAF1, CNTN4, PPP2R2B, TENM2, CSMD1). We also 
found significant enrichment of pleiotropic risk genes in multiple measures of body mass 
index (BMI), supporting previous studies suggesting a shared etiologic basis between a 
range of neuropsychiatric disorders and obesity (Hartwig et al., 2016; Lopresti and 
Drummond, 2013; Milaneschi et al., 2018) 
 
 
DISCUSSION   
 
In the largest cross-disorder GWAS meta-analysis of neuropsychiatric disorders to date, 
comprising more than 725,000 cases and controls across eight disorders, we identified 
146 LD-independent lead SNPs associated with at least one disorder, including 35 
novel loci. Of these, 109 loci were found to affect two or more disorders, although 
characterization of this pleiotropy is partly dependent on per-disorder sample size. Our 
results provide four major insights into the shared genetic basis of psychiatric disorders.  
  
First, modeling of genetic correlations among the eight disorders using two different 
methods (EFA and hierarchical clustering) identified three groups of disorders based on 
shared genomics: one comprising disorders characterized by compulsive behaviors 
(AN, OCD and TS), a second comprising mood and psychotic disorders (MD, BIP and 
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SCZ), and a third comprising two early-onset neurodevelopmental disorders (ASD and 
ADHD) and one disorder each from the first two factors (TS and MD). The loading of 
MD on two factors may reflect biological heterogeneity within MD, consistent with recent 
evidence showing that early-onset depression is associated with genetic risk for ADHD 
and with neurodevelopmental phenotypes (Rice et al., 2018). Overall, these results 
indicate a substantial pairwise genetic correlation between multiple disorders along with 
a higher-level genetic structure that point to broader domains underlying genetic risk to 
psychopathology. These findings are at odds with the classical, categorical classification 
of mental illness.   
  
Second, variant-level analyses support the existence of substantial pleiotropy, with 
nearly 75% of the 146 genome-wide significant SNPs influencing more than one of the 
eight examined disorders. We also identified a set of 23 loci with particularly extensive 
pleiotropic profiles, affecting four or more disorders. The most highly pleiotropic locus in 
our analyses, with evidence of association with all eight disorders, maps within DCC, a 
gene fundamental to the early development of white matter connections in the brain 
(Bendriem and Ross, 2017). Prior studies showed that DCC is a master regulator of 
axon guidance (through its interactions with netrin-1 and draxin (Liu et al., 2018). Loss 
of function mutations in DCC cause severe neurodevelopmental syndromes involving 
loss of midline commissural tracts and diffuse disorganization of white matter tracts 
(Bendriem and Ross, 2017; Jamuar et al., 2017; Marsh et al., 2017). A highly pleiotropic 
effect of variation in DCC on diverse psychiatric disorders with childhood and 
adolescent onset would be consistent with its role in both early organization of neuronal 
circuits and the maturation of mesolimbic dopaminergic connections to the prefrontal 
cortex during adolescence (Hoops and Flores, 2017; Reynolds et al., 2018; Vosberg et 
al., 2018).   
  
We also identified a set of loci that have opposite effects on risk of psychiatric disorders.  
Notably, these included loci with opposing effects on pairs of disorders that are 
genetically correlated and have common clinical features. For example, a SNP within 
MRSA was associated with opposing effects on two neurodevelopmental disorders 
(ASD and SCZ), and a variant within KIAA1109 had opposite directional effects on 
major mood disorders (BIP and MD) (Supplementary Table 6). These results 
underscore the complexity of genetic relationships among related disorders and suggest 
that overall genetic correlations may obscure antagonistic biological mechanisms that 
operate at the level of component loci and pathways as seen in immune-mediated 
diseases (Baurecht et al., 2015; Lettre and Rioux, 2008; Schmitt et al., 2016). This 
heterogeneity of effects between genetically correlated disorders is also consistent with 
a recent analysis that revealed loci contributing to biological differences between BIP 
and SCZ and found polygenic risk score associations with specific symptom dimensions 
(Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics 
Consortium, 2018). 
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Third, we found extensive evidence that neurodevelopmental effects underlie the cross-
disorder genetics of mental illness. In addition to DCC, a link between pleiotropy and 
genetic effects on neurodevelopment was also seen for other top loci in our analysis, 
including RBFOX1, BRAF, and KDM7A, all of which have been shown in prior research 
to influence aspects of nervous system development. Gene enrichment analyses 
showed that pleiotropic loci were distinguished from disorder-specific loci by their 
involvement in neurodevelopmental pathways including neurogenesis, regulation of 
nervous system development, and neuron differentiation. These results are consistent 
with those of a smaller recent analysis in the population-based Danish iPSYCH cohort 
(comprising 46,008 cases and 19,526 controls across six neuropsychiatric disorders) 
(Schork et al., 2017). In that analysis, consistent with the present findings, functional 
genomic characterization of cross-disorder loci implicated fetal neurodevelopmental 
processes, with greater prenatal than postnatal expression. However, the specific loci, 
cell types, and pathways implicated in the iPSYCH analysis differed from those 
identified in our study. Of note, however, SORCS3 emerged as a genome-wide 
significant cross-disorder locus in both studies.   
  
Fourth, our analyses of spatiotemporal gene expression profiles revealed that 
pleiotropic loci are enriched among genes expressed in neuronal cell types, particularly 
in frontal or prefrontal regions. They also demonstrated a distinctive feature of genes 
related to pleiotropic loci: compared with disorder-specific loci, they are on average 
expressed at higher levels both prenatally and postnatally (Figure 4). More specifically, 
single-disorder (mainly SCZ) loci were related to genes that were preferentially 
expressed in the first fetal trimester followed by a decline over the prenatal period and 
then relatively stable levels postnatally. In contrast, expression of genes related to 
pleiotropic loci peaked in the second trimester and remained overexpressed throughout 
the lifespan. When dividing the pleiotropic loci into bins of those associated with two 
disorders (mainly SCZ and BIP) vs. three or more disorders, we observed a consistent 
gradient of greater expression associated with broader pleiotropy.    
  
Taken together, our results suggest that pleiotropic loci appear to be distinguished by 
both their differential importance in neurodevelopmental processes and their heightened 
brain expression after the first trimester. Apart from this, however, pleiotropic loci were 
similar to non-pleiotropic loci across a range of other functional features, including 
intolerance to loss-of-function mutations, evidence of selection, minor allele frequencies, 
and genomic position relative to functional elements.     
  
Overall, our results identify a range of pleiotropic effects among loci associated with 
psychiatric disorders. Consistent with prior research (Brainstorm Consortium, 2018; 
Cross-Disorder Group of the Psychiatric Genomics Consoritum, 2013), we found 
substantial pairwise genetic correlations across child- and adult-onset disorders and 
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extended these findings by demonstrating clusters of genetically-related disorders. 
These results augment a substantial body of research demonstrating that genetic 
influences on psychopathology do not map cleanly onto the clinical nosology 
instantiated in the DSM or ICD (Smoller et al., 2018). Using a range of bioinformatic and 
functional genomic analyses, we find that loci with pleiotropic effects are distinguished 
by their involvement in early neurodevelopment and increased expression beginning in 
the second trimester of fetal development and persisting throughout adulthood. Taken 
together, the analyses presented here suggest that genetic influences on psychiatric 
disorders comprise at least two general classes of loci. The first comprises a set of 
genes that confer relatively broad liability to psychiatric disorders by acting on early 
neurodevelopment and the establishment of brain circuitry. These pleiotropic genes 
begin to come online by the second trimester of fetal development and exhibit 
differentially high expression thereafter. Such loci may underlie a latent general 
psychopathology factor (the “p” factor) (Caspi et al., 2014) that has been identified in 
developmental studies of mental disorders, comprising transdiagnostic symptom 
clusters (internalizing, externalizing, and psychotic) (Caspi et al., 2014). The expression 
and differentiation of this generalized genetic risk into discrete psychiatric syndromes 
(e.g., ASD, BIP, AN) may then involve direct and/or interactive effects of additional sets 
of loci and environmental factors, possibly mediated by epigenetic effects, that shape 
phenotypic expression via effects on brain structure/function and behavior. Further 
research will be needed to clarify the nature of such effects.   
  
Our results should be interpreted in light of several limitations. First, while our dataset is 
the largest genome-wide cross-disorder analysis to date, data available for individual 
disorders varied substantially—from a minimum of 9,725 cases and controls for OCD to 
461,134 cases and controls for MD. This imbalance of sample size may have limited our 
power to detect pleiotropic effects on underrepresented disorders. Second, it is possible 
that comorbidity among disorders contributed to apparent pleiotropy; however we found 
that less than 2% of cases overlapped between disorder datasets (excluding 23andMe 
data) and we adjusted for overlap in meta-analysis. Third, the method we applied to 
detect cross-phenotype association, which combines an all-subsets fixed-effects GWAS 
meta-analysis with a Bayesian method for evaluating the best-fit configuration of 
genotype-phenotype associations, is one of several approaches (Solovieff et al., 2013). 
However, we have previously shown that this method outperforms a range of 
alternatives for detecting pleiotropy under various settings (Zhu et al., 2018). Fourth, our 
designation of loci as pleiotropic vs. non-pleiotropic loci refers only to their observed 
effects on the eight target brain disorders. Thus, some of the “non-pleiotropic” loci may 
have additional effects on psychiatric phenotypes that were not included in our meta-
analysis and/or on non-psychiatric phenotypes. Fifth, our functional genomic analyses 
were constrained by the limitations of existing resources (e.g. spatiotemporal gene 
expression data resources). Our work underscores the need for more comprehensive 
functional data including single cell transcriptomic and epigenomic profiles across 
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development and brain tissues. Lastly, we included only individuals of European 
ancestry to avoid potential confounding due to ancestral heterogeneity across distinct 
disorder studies. Similar efforts are needed to examine these questions in other 
populations. 
  
In sum, in a large-scale cross-disorder genome-wide meta-analysis, we identified three 
genetic factors underlying the genetic basis of eight psychiatric disorders. We also 
identified 109 genomic loci with pleiotropic effects, of which 33 have not previously been 
associated with any of the individual disorders. In addition, we identified 11 loci with 
opposing directional effects on two or more psychiatric disorders. These results 
highlight disparities between our clinically-defined classification of psychiatric disorders 
and underlying biology. Future research is warranted to determine whether more 
genetically-defined influences on cross-diagnostic traits or subtypes of dissect may 
inform a biologically-informed reconceptualization of psychiatric nosology.  Finally, we 
found that genes associated with multiple psychiatric disorders are disproportionately 
associated with biological pathways related to neurodevelopment and exhibit distinctive 
gene expression patterns, with enhanced expression beginning in the second prenatal 
trimester and persistently elevated expression relative to less pleiotropic genes. 
Therapeutic modulation of pleiotropic gene products could have broad-spectrum effects 
on psychopathology.     
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Supplementary Figure Titles and Legends  
  
Figure S1. Hierarchical clustering of genetic architecture across eight 
neuropsychiatric disorders. (Related to Table S3) Hierarchical clustering revealed 
three sub-groups within the eight disorders. Results were very similar to those obtained 
using exploratory factor analysis and genomic structural equation modeling.  
 
Figure S2. P-M plots for top 146 loci. (Related to Figure 3 and Table S5) M-values 
were generated for each locus for each disorder and indicate the presence or absence 
of a disorder-specific effect. M-values were plotted with the negative log odds of the 
corresponding p-values for each disorder for a given SNP; P-M plots were generated for 
each of the top 146 loci. Log odds ratios for the effect of the SNP on each disorder and 
a summary across disorders was also plotted. As expected, most of the top SNPs 
(109/146) were pleiotropic.  
 
Figure S3. Statistical power and number of cross-disorder associations (Related 
to Table S4). Power to detect associations across pairs of disorders was plotted with 
the number of cross-disorder associations identified in the current meta-analysis. For 
each pair of disorders, power was estimated using the number of cases and heritability 
for each disorder, as well as the genetic correlation between the disorders. In general, 
as power increased, so did the number of SNPs identified. 
 
Figure S4. Gene expression of top loci across development. (Related to Figure 3) 
Gene expression trajectories from a transcriptome atlas of post-mortem brain tissue 
across development are plotted for four top loci, DCC, RBFOX1, NOX4 and BRAF in six 
different brain tissue types. AMY = amygdala; MD = mediodorsal nucleus of the 
thalamus; CBC = cerebellar cortex; NCX = neocortex; HIP = hippocampus; STR = 
striatum.  
 
Figure S5. Gene expression in the brain for pleiotropic and non-pleiotropic loci. 
(Related to Figure 5) Average normalized gene expression in fetal and adult post-
mortem brain tissue for pleiotropic (109) and non-pleiotropic (37) loci were plotted. 
Disorder-specific and pleiotropic risk loci showed a similar level of gene expression in 
prenatal and postnatal development after multiple testing correction (t-test p > 0.025).  
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STAR* METHODS  
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
 
Any inquiries about analytical results or other information should be directed to Phil H. 
Lee (plee0@mgh.harvard.edu) or Jordan W. Smoller (jsmoller@mgh.harvard.edu).  
 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
 
Genotyped sample description 
Genotype data from eight studies of genetic associations with psychiatric disorders 
conducted by the Psychiatric Genomics Consortium were included in this report. A 
summary of each study is provided below, however, detailed sample descriptions are 
available in the primary publication. The lead PI of every cohort included across studies 
certified that their protocol was approved by their local Ethical Committee. 
Supplementary Table 1 lists for each disorder the number of cases and controls, the 
number of loci identified in the single disorder genome-wide association study, and 
SNP-based heritability. 
 
Schizophrenia | Ripke et al., 2014 
 108 loci were identified as associated with schizophrenia in a case-control meta-
analysis including 150,064 individuals. For the current study, the 46 case-control 
cohorts of European ancestry were retained, totaling 33,640 cases and 43,546 controls. 
Cases were defined as individuals diagnosed with schizophrenia or schizoaffective 
disorder, which was determined by research-based assessment or clinician diagnosis 
depending on the sample.  
 
Bipolar disorder | Stahl et al., 2018 
 Thirty-two case-control cohorts from Europe, North America, and Australia 
including 20,352 cases and 31,358 controls of European ancestry were meta-analyzed 
to identify 30 loci associated with bipolar disorder. Cases met criteria for lifetime 
diagnosis of bipolar disorder as defined by DSM-IV, ICD-9, or ICD-10, which was 
established using interview-based structured assessment, clinician-administered 
checklists, or review of medical records. All subjects in the meta-analysis were included 
in the current study. 
 
Major depression | Wray et al., 2018 
 Seven case-control cohorts were combined to identify 44 loci associated with 
major depression. The first cohort included 29 case-control samples of European 
descent where lifetime diagnosis of major depressive disorder was ascertained using 
structured clinical interviews (DSM-V, ICD-9, ICD-10), clinician-administered checklists, 
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or review of medical records. Six additional cohorts of European ancestry, including the 
Hyde et al study (23andMe, Inc), determined case status using other methods including 
national or hospital treatment registers, self-reported symptoms or treatment by a 
medical professional, or direct interviews. Analyses comparing the original cohort with 
the additional ones indicated strong correlation of common genetic variants and little 
evidence of heterogeneity. 130,664 cases and 330,470 controls from these cohorts 
were included in the current analyses.  
 
Attention deficit hyperactive disorder | Demontis et al., 2019 
 Twelve cohorts of European, North American, and Chinese descent were 
aggregated in a meta-analysis of attention deficit and hyperactive disorder, revealing 12 
associated loci. For the first cohort, cases were ascertained using the Danish 
Psychiatric Central Research Registrar and diagnoses were confirmed by psychiatrists 
according to ICD-10. The remaining studies included four parent-offspring trio cohorts 
and seven case-control cohorts. Cases were recruited from clinics, hospitals or through 
medical registries and diagnosed using research-based assessments administered by 
clinicians or trained staff. 19,099 cases and 34,194 controls of European ancestry were 
included in the current study.   
 
Autism spectrum disorder | Grove et al., 2017 
 Five family-based cohorts of European descent and a population-based case-
control sample from Denmark were combined to discover five loci associated with 
autism spectrum disorder. In each family study, diagnosis was confirmed for all affected 
individuals using standard research tools and expert clinical consensus diagnosis. In the 
population-based cohort, cases were identified using the Danish Psychiatric Central 
Research Register and were diagnosed with ASD before 2013 by a psychiatrist 
according to ICD-10. All subjects in this sample were included here (18,381 cases; 
27,969 controls). 
 
Obsessive compulsive disorder | IOCDF-GC and OCGAS, 2018 
 Individuals of European descent from two cohorts were combined in this meta-
analysis including 2,688 cases and 7,037 controls; no loci reached genome-wide 
significance. Case diagnoses were established using DSM-IV criteria and controls were 
unscreened. All cases and controls were included in the current analyses.  
 
Anorexia nervosa | Duncan et al., 2017 
 3,495 cases from two consortia and 10,982 matched controls from the 
Psychiatric Genomics Consortium, all of European descent, were meta-analyzed to 
identify one locus associated with anorexia nervosa. Cases met criteria as defined by 
DSM-IV for lifetime diagnosis of anorexia nervosa (restricting or binge-purging subtype), 
bulimia nervosa, or anorexia nervosa – not otherwise specified, anorexia nervosa 
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subtype. All individuals included in the primary study were included in the current 
analyses.  
 
Tourette Syndrome | Yu et al., in press, American Journal of Psychiatry 
Three case-control cohorts and one family-based cohort from Europe and North 
America including 4,819 cases and 9,488 controls of European ancestry were meta-
analyzed to identify one locus associated with Tourette Syndrome. All cases met DSM-
IV-TR or DSM-5 criteria for Tourette syndrome, except for 12 cases who met DSM-5 
criteria for chronic motor or vocal tic disorder. All cases were recruited by Tourette 
syndrome specialty clinics or by email/online recruitment combined with validated, web-
based phenotypic assessments.  
 
Genotype quality control, imputation, and association analysis 
All primary studies used the standardized PGC ricopili pipeline for quality control, 
imputation and association testing. Briefly, for each dataset, poor quality SNPs and 
samples missing >5% SNPs were removed. Next, pre-phasing and imputation were 
implemented using IMPUTE2 (Howie et al., 2011) and the 1000 Genomes reference 
panel. High quality SNPs (INFO > 0.8) with low missingness (<1%) were retained. A 
subset of these markers (MAF > 0.05; pruned for linkage disequilibrium, r2 > 0.02) were 
used to assess relatedness and population stratification. Only one of any pair of related 
individuals was retained. Each imputed dataset was tested for association with the 
disease outcome of interest using an additive logistic regression model in PLINK 
(Purcell et al., 2007) with age, sex, and 10 principal components included as covariates. 
Finally, a meta-analysis within each disease category was done using an inverse-
weighted fixed effects model. After extracting SNPs commonly exist in all eight disorder 
studies, we removed 3,591 SNPs whose alleles were incompatible. For palindromic 
SNPs, we compared allele frequencies between eight studies to check strand 
ambiguity. 50 SNPs with frequency difference greater than 15% from the 1KG reference 
was excluded. As a result, 6,786,994 autosomal SNPs remained for further analysis. 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
Genome-wide SNP-heritability estimation 
For each of the eight GWAS disorders, LD Score regression was performed on the 
summary statistics of individual disease using LDSC to estimate SNP-based heritability 
in the liability scale and genetic correlation between pairs of disorders (Bulik-Sullivan et 
al., 2015b). LD scores and weights for European populations were downloaded from the 
LDSC website (http://www.broadinstitute.org/~bulik/eur_ldscores/). SNPs were removed 
if the minor allele frequency is smaller than 5% or an imputation quality score is less 
than 0.9; MHC region was excluded from the analysis. For single-trait LDSC, the slope 
of the regression estimates the SNP-based heritability, and the intercept captures the 
inflation in the summary statistics due to population stratification or other confounding 
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factors. We confirmed that the heritability Z-scores (i.e., a measure of the polygenic 
signals) are greater than four, and the LDSC intercepts are approximately one and less 
than 𝜆$%. This suggests that the increase in mean χ2 statistics is mostly due to 
polygenicity and not due to stratification. 
 
Factor analysis and genomic SEM 
Genomic SEM’s Multivariable LD score regression method (Grotzinger et al., 2018) was 
first used to estimate the genetic covariance matrix (S) and sampling covariance matrix 
(V) for the eight psychiatric traits. Quality control for this step included removing SNPs 
with an MAF < 1%, information scores < .9, SNPs from the MHC region, and filtering 
SNPs to HapMap3. All SNP effects were standardized using the sumstats function in 
Genomic SEM. To examine genome-wide factor structure, models using only the 
genetic covariance and sampling covariance matrix were fit. Genomic SEM provides 
indices of model fit—standardized root mean square residual (SRMR), model c2, Akaike 
Information Criteria (AIC), and Comparative Fit Index (CFI)—that can be used to 
determine how well the proposed model captures the observed data. Model fit for the 
common factor model in which the loadings were freely estimated was only fair, (c2 (20) 
= 313.94, AIC = 345.9, CFI = .786, SRMR = .149), suggesting that there were nuances 
in the genetic architecture not fully captured by a single cross-trait index of genetic risk. 
An exploratory factor analysis (EFA) of the S matrix with three-factors using the promax 
rotation in the R package factanal was then used to guide construction of a follow-up 
model (Supplementary Table 3). A follow-up confirmatory model with three correlated 
factors was specified in Genomic SEM based on the EFA parameter estimates (positive 
standardized loadings > .2 were retained; Figure 2b). This model provided good fit to 
the data (c2 (15) = 85.35, AIC = 127.36, CFI = .945, SRMR = .079). Results indicated 
there was a moderate genetic correlation between the compulsive and mood/psychotic 
disorders factors (rg = .43, SE = .07), a smaller genetic correlation between the 
mood/psychotic and early onset factors (rg = .24, SE = .05), and next to no correlation 
between the compulsive and early onset factors (rg = < .01, SE = .07). A model that 
included additional negative cross-loadings provided similar fit to the data and highly 
similar correlations across the genetic factors. Given this consistency in results, the 
correlated factors model with SNP effects only included positive loadings. 
 
Summary-data-based meta-analysis 
To identify genomic loci shared across multiple neuropsychiatric disorders, we 
performed primary meta-analysis using the subset-based fixed-effects method ASSET 
(Bhattacharjee et al., 2012). Standard meta-analysis pools the effect of a given SNP 
across K studies, weighting the effects by the size of the study. In this subset-based 
meta-analysis, this basic procedure – as well as a null probability distribution for a SNP 
having no effect in any study – was calculated for all subsets of studies to determine a 
given SNP’s subset-specific effect. The maximum SNP effect across subsets can be 
denoted 
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𝑍'()*'+,( = 𝑚𝑎𝑥1∈𝑺|𝑍(𝑆)|, 
 
where the absolute value of the subset-specific effect [Z(S)] over class S of all possible 
subsets of K studies is highest. The numbers of shared subjects across eight disorder 
studies were identified using the PGC checksum algorithm, and Zmeta was standardized 
so that covariance between the statistics can be accounted for as previously described 
(Bhattacharjee et al., 2012; Lin and Sullivan, 2009).  Tail probabilities for the distribution 
of the maximum were then estimated with the discrete local maxima method, which 
uses the correlation structure of test statistics across subsets. Based on this distribution, 
a p-value was derived using a one-sided test of the test statistic (Z); each directional 
test can then be combined using a chi-square method (Fisher’s combined p-value 
method). Even when correcting for all subset tests (2K-1), simulations suggest there is a 
substantial gain in power using this test relative to traditional meta-analysis.  
 
Once SNPs with genome-wide significant association were identified, we identified LD-
independent genomic regions using PLINK clumping (--clump-r2=0.4, --clump-kb=500, -
-clump-p1=5e-08, --clump-p2=5e-02). Genomic regions were merged if they physically 
overlap using bedtools. Due to extensive LD, the MHC region was considered as one 
region (chr6:25-35Mb). To detect secondary signals independent of index SNP in each 
of the candidate cross-disorder loci, conditional analysis was performed with GCTA-
COJO (Yang et al., 2012) using meta-analysis summary statistics from ASSET. 1KG 
EUR population was used as the reference panel for estimating LD. For each genomic 
region harboring a cross-disorder signal, we tested the presence of any additional 
associated SNPs using a stepwise procedure (--cojo-slct), conditioning on the primary 
significant SNP for model initiation. A conditional p-value for each variant was reported, 
adjusted for genomic control and collinearity. In each region, additional SNPs were 
selected as a distinct association signal if having a conditional p-value < 1e-06. 
 
Disease-association modeling 
We estimated posterior probabilities for each of the top loci identified from the meta-
analysis to quantify disorder-specific effects (Han and Eskin, 2012). This estimation, 
known as the m-value, relies on two assumptions, 1) effects are either present or 
absent in studies, and 2) if they are present, they are similarly sized across studies. 
Assume Xi is the observed effect size of study i, and Ti is a random variable with value 1 
if study i has an effect and 0 if not, then the m-value can be estimated using Bayes’ 
theorem: 𝑚8 = 𝑃(𝑇8 = 1|𝑋) = 𝑃(𝑋|𝑇8 = 1)𝑃(𝑇8 = 1)𝑃(𝑋|𝑇8 = 0)𝑃(𝑇8 = 0) + 𝑃(𝑋|𝑇8 = 1)𝑃(𝑇8 = 1) 
 
which can then be used to predict whether an effect exists in a given study (>.9) or not 
(<.1) under the binary effects assumption. For further details, refer to the publication by 
Han & Eskin (2012).  
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Functional annotation and gene-mapping of genome-wide significant variants  
For the 146 genome-wide significant variants, gene mapping and functional annotation 
was conducted using various resources, including SNPNexus (Dayem et al., 2018) and 
FUMA (Watanabe et al., 2017). Nearest genes and functional consequence of each 
SNP on gene functions were annotated based on ANNOVAR (Wang et al., 2010). 
Combined Annotation Dependent Depletion (CADD) score (Kircher, 2014) indexes the 
deleteriousness of variants computed based on 67 annotation resources. SNPs with the 
CADD score higher than 12 were considered to confer deleterious effects. The 
RegulomeDB (Boyle, 2012) provides a categorical score that describes how likely a 
SNP is likely to play a regulatory role based on the integration of high-throughput 
datasets. The RDB score of 1a suggests the strongest evidence while the score 7 
represents the least support for a regulatory potential. The minChrState and the 
commonChrState represent the minimum and the most common15-core chromatin state 
across 127 tissue/cell type predicted by ChrHMM. The chromatin state of less than 8 
suggests an open chromatin state. We also performed eQTL mapping, which provides 
significant cis-SNP-gene pairs (up to 1Mb apart) in brain tissue types from GTEx and 
BRAINEAC.  
 
For chromatin interaction mapping, we first refined the localization of potential causal 
variants for top 146 lead SNPs. We then used FINEMAP (Benner et al., 2016) to identify 
credible SNPs. For each region, we considered only SNPs located in the LD region with 
the lead SNP (r2 > 0.6). We then applied the method to calculate the posterior 
probability of being causal for each of the remaining SNPs. A 95% credible set of SNPs 
for each region was constructed by ordering the posterior probability from largest to 
smallest and selecting in the corresponding SNPs up to a cumulative probability of 95%. 
Credible SNPs were then grouped into those that are located within the promoter or 
exons and those that are non-coding/intronic. Promoter/exonal SNPs were directly 
assigned to their target genes using positional mapping, while non-coding/intronic SNPs 
were assigned to their target genes based on long range interactions (Hi-C) or 
expression quantitative trait loci (eQTLs). Two Hi-C datasets originated from the human 
brain (fetal brain Hi-C (Won et al., 2016) and adult brain Hi-C (Wang et al., 2018)) were 
used to map credible SNPs as previously described (Wang et al., 2018). A 
colocalization analysis with the recent eQTL dataset from adult prefrontal cortices (PFC) 
was also used to map 146 GWS loci into their target genes (Wang et al., 2018). In the 
end, we obtained two sets of candidate genes, one from fetal brain (positional mapping, 
fetal brain Hi-C), the other from adult brain (positional mapping, adult brain Hi-C, adult 
brain eQTLs).     
 
GTEx gene expression enrichment analysis 
MAGMA gene-property analysis (de Leeuw et al., 2015) was performed using gene 
expression data from 83 tissues based on GTEx RNA-seq data (v7). Expression values 
(RPKM) were log2 transformed with pseudo-count one after winsorization at 50, and 
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average expression values were taken per tissue. Analysis was performed separately 
for 30 general tissue types and 53 specific tissue types.  
 
Pathway analysis using Gene Ontology 
We used FUMA (Watanabe et al., 2017) to map SNPs to genes and then test for 
enrichment of specific Gene Ontology functions and pathways among genome-wide 
significant pleiotropic and disorder-specific SNPs separately. Hypergeometric tests 
identify any statistical over-representation of genes from the input list (mapped from 
SNPs) in predefined Gene Ontology gene sets which describe biological processes, 
molecular functions, and cellular components. Multiple test correction was applied by 
category. 
 
Enrichment analysis using brain developmental, regional, and cell-type-specific 
data  
Developmental expression trajectories for candidate genes were plotted using a 
published transcriptome atlas constructed from post-mortem brain data (Kang et al. 
2011). Expression values were log-transformed and centered using the mean 
expression values for all brain expressed genes. Mean expression values for candidate 
genes were plotted across prenatal (6-37 weeks post-conception) and postnatal (4 
months to 62 years) developmental stages. We used candidate genes identified in fetal 
brain and adult brain to plot prenatal and postnatal gene expression profiles, 
respectively.  
 
To obtain genes that show cortical regional enrichment (e.g. frontal cortical enrichment), 
we computed t-statistics for each gene for a specific cortical region (e.g. frontal cortex) 
versus all other cortical regions (e.g. parietal cortex, temporal cortex, and occipital 
cortex, Kang et al. 2011). Top 5% of genes that show specific expression patterns for 
each cortical region were selected as region-specific genes. These genes were then 
overlapped with candidate genes by Fisher’s exact test to measure cortex regional 
enrichment. 
 
Single cell expression profiles from the adult brain (Darmanis et al., 2015) were used to 
identify cell-type specificity of candidate genes. Single cell expression values were log-
transformed and centered using the mean expression values. Average centered 
expression values for candidate genes were calculated in each cell. Cells were then 
grouped into cell clusters (neurons, astrocytes, microglia, oligodendrocytes, OPC, and 
endothelial cells), and a relative expression level for a given cell cluster was calculated 
by a scale function in R. 
 
Developing neural cell-type enrichments were estimated using expression profiles of 
single-cells taken from fetal cortical laminae. Cell-type specific genes were selected 
according to a significant Pearson correlation (FDR < 0.05) between the gene and an 
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idealized cluster marker for each cell-type, following the approach described in original 
publication. Candidate gene enrichment for each set of specifically expressed genes 
was estimated by logistic regression and adjusting for gene length.  
   
Comparison with other brain-related traits and diseases  
To look for other traits that show an association with our top loci, we examined publicly 
available GWAS summary statistics of 11 brain-related and 10 non-brain-related traits 
and disorders. The selected brain-related traits include Alzheimer’s disease (Lambert et 
al., 2013), anxiety (Otowa et al., 2016), all epilepsies (International League Against 
Epilepsy Consortium on Complex Epilepsies. Electronic address, 2014), genetic 
generalized epilepsy (International League Against Epilepsy Consortium on Complex 
Epilepsies. Electronic address, 2014), non-acquired focal epilepsy (International League 
Against Epilepsy Consortium on Complex Epilepsies. Electronic address, 2014), 
intracerebral hemorrhage (Woo et al., 2014), post-traumatic stress disorder (Duncan et 
al., 2018), ischemic stroke (all) (Malik et al., 2016), cardioembolic stroke (Malik et al., 
2016), large-vessel disease(Malik et al., 2016), and small vessel disease(Malik et al., 
2016), non-brain-related traits include height (Wood et al., 2014), obesity (Berndt et al., 
2013), Crohn's disease (Goyette et al., 2015; Liu et al., 2015), inflammatory bowel 
disease (Goyette et al., 2015; Liu et al., 2015), ulcerative colitis (Goyette et al., 2015; 
Liu et al., 2015), coronary artery disease (Nikpay et al., 2015), sleep duration(Jones et 
al., 2016), number of children ever born (Barban et al., 2016), subject well-being (Okbay 
et al., 2016), and neuroticism (Okbay et al., 2016). Data source and sample size 
information for each individual GWAS can be found in Table S16. All the summary 
results files were harmonized before use, with reference and effect alleles matched up 
across studies for each index SNP. We then extracted the association statistics of the 
lead SNPs—effect sizes with standard errors (or Z-scores) and p-values—with each of 
the traits listed herein. Where the index variant was not available, the nearest proxy 
SNP (r2 > 0.8) was used for reporting the association. 
 
DATA AND SOFTWARE AVAILABILITY 
The Psychiatric Genetics Consortium (PGC)’s policy is to make genome-wide summary 
results publicly available. Summary statistics for a combined meta-analysis of eight 
psychiatric disorders without 23andMe data are available on the PGC web site 
(https://www.med.unc.edu/pgc/results-and-downloads).  Results for 10,000 SNPs for 
eight disorders including 23andMe are also available on the PGC web site. The 
summary-level GWAS association statistics for PGC individual disorders are available 
at the website (https://www.med.unc.edu/pgc/results-and-downloads). 
GWAS summary statistics for the 23andMe cohort (Hyde, 2016) must be obtained 
separately. These can be obtained by individual researchers under an agreement with 
23andMe that protects the privacy of the 23andMe participants. Contact Aaron 
Petrakovitz (apetrakovitz@23andme.com) to apply for access to the data.   
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 Supplementary Tables 
 
Table S1. Summary of eight neuropsychiatric disorder datasets (Related to Table 
1). Disease-specific cases and controls included in the meta-analysis, number of 
individual GWAS loci, and liability-based SNP heritability estimates are provided. 
Heritability was estimated from available European summary statistics using LD score 
regression. 
 
Table S2. Genetic correlations estimated by LD score regression. (Related to 
Figure 1) Genetic correlations and standard errors between pairs of disorders were 
estimated from European GWAS summary statistics using LD score regression. 
 
Table S3. Results from EFA of genetic covariance matrix (Related to Figure 1 and 
Figure S1) 
We estimated the genetic covariance matrix across eight psychiatric traits using 
genomic SEM and then performed an exploratory factor analysis, which revealed three 
factors. Individual disease loadings on each factor are listed as well as correlations 
between factors.  
 
Table S4. List of 146 lead SNPs (Related to Figure 3 and Figure S2) 
The cross-disorder fixed-effects meta-analysis identified 136 loci and within these loci, 
multi-SNP-based conditional analyses identified 10 additional SNPs. The details of 
these 146 lead SNPs, as well as the posterior probability of disease-specific 
associations estimated using a Bayesian statistical framework are listed.  
 
Table S5. Disorder-specific association (Related to Figure 3 and Figure S2) 
Disease-specific associations are listed for all 146 lead SNPs.  
 
Table S6. Loci with opposite directional effects  
(Related to Figure 4) 
SNPs with a cross-disorder meta-analysis p ≤ 1x10-6 that showed disorder-specific 
effects in opposite directions are listed along with the effects for each disease.  
 
Table S7. Functional annotation of 146 lead SNPs (Related to Table S4) 
Functional annotation for the genome-wide significant SNPs was done using 
SNPNexus, FUMA, and ANNOVAR. SNPs were mapped to the nearest gene within 
100kb when possible and various functional consequences were annotated including 
combined annotation dependent depletion (CADD) scores, which reflect the 
deleteriousness of variants based on 67 annotation resources, and likelihood SNP plays 
a regulatory role based on the RegulomeDB (1 = strongest; 7 = weakest).  
 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/528117doi: bioRxiv preprint first posted online Jan. 26, 2019; 
Table S8. Brain eQTL and Hi-C data annotation based on FUMA database (Related 
to Table S4) 
Genome-wide significant SNPs were tested for any eQTL effects in brain tissues. 
Significant cis-SNP-gene pairs (up to 1Mb apart) identified in GTEx (v7) or BRAINEAC 
are listed along with associated p-values. Additionally, fine-mapping for the 146 lead 
SNPs was done using an efficient summary statistics-based Bayesian method to 
identify a 99% credible set of SNPs for each region. These SNPs were used to identify 
long-range interactions with the regions harboring a candidate SNP using brain Hi-C 
datasets. The Hi-C tissue, regions, and p-values were reported.  
 
Table S9. GWAS catalog data for lead SNPs (Related to Table S4) 
The NHGRI-EBI GWAS Catalog was queried for each SNP to identify all traits 
previously associated with a lead SNP (p-value < 1x10-5), along with the corresponding 
effect sizes and p-values.  
 
Table S10. GTEx gene enrichment analysis using MAGMA (Related to Figure 5) 
To investigate enrichment of lead SNPs within certain tissue types, we performed a 
MAGMA gene-property analysis using gene expression data from 83 tissues based on 
GTEx RNA-seq data (v7). Enrichment statistics for each tissue are listed.  
 
Table S11. Tissue enrichment analysis for pleiotropic risk loci using MAGMA 
(GTEx v7) (Related to Figure 5) 
To evaluate pleiotropic-specific effects, we assessed enrichment for the 109 pleiotropic 
lead SNPs using MAGMA and 83 tissues based on GTEx v7. The statistics for each 
tissue are listed.  
 
Table S12. Tissue enrichment analysis for disorder-specific risk loci using 
MAGMA (GTEx v7) (Related to Figure 5) 
To evaluate disorder-specific effects, we assessed enrichment for non-pleiotropic lead 
SNPs using MAGMA and 83 tissues based on GTEx v7. The statistics for each tissue 
are listed.  
 
Table S13. Gene ontology analysis for pleiotropic loci (Related to Result - 
Functional characterization of pleiotropic risk loci) 
We used Gene Ontology data to identify any enrichment among the 109 pleiotropic 
SNPs for specific biological processes (GO_bp), molecular functions (GO_mf), or 
cellular components (GO_cc). Gene sets for which significant enrichment was identified 
are listed along with raw and adjusted p-values.  
 
Table S14. GO enrichment analysis for disease-specific risk loci (Related to 
Result - Functional characterization of pleiotropic risk loci) 
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We used Gene Ontology data to identify any enrichment among the 37 disease-specific 
loci for specific biological processes (GO_bp), molecular functions (GO_mf), or cellular 
components (GO_cc). Gene sets for which significant enrichment was identified are 
listed along with raw and adjusted p-values.  
 
Table S15. GWAS Catalog enrichment analysis for top genome-wide significant 
loci (Related to Result - Functional characterization of pleiotropic risk loci) 
For traits in the NHGRI-EBI GWAS Catalog, we mapped genome-wide significant loci to 
genes and then assessed the overlap between genes for a given trait and genes linked 
to the top loci for the current meta-analysis. We calculated p-values associated with the 
degree of overlap relative to what would have been expected by chance.  
 
Table S16. Comparison of disease-specific vs. pleiotropic risk loci by various 
functional and genomic features (Related to Result - Functional characterization 
of pleiotropic risk loci) 
Functional and genomic features were compared between pleiotropic and non-
pleiotropic loci. Statistics from t-tests, as well as ANOVAs, comparing these two groups 
were reported.  
 
Table S17. Genetic correlation analysis of top cross-disorder loci with 28 brain-
related traits (Related to Result - Relationship between cross-disorder genetic 
risk and other brain-related traits and diseases) 
We used LD score regression to estimate genetic correlations between cross-disorder 
risk and 28 other publicly available brain-related traits. These effects, along with data 
source and sample size information for each individual GWAS were listed.  
 
Table S18. GWAS catalog enrichment analysis for pleiotropic risk loci (Related to 
Result - Relationship between cross-disorder genetic risk and other brain-related 
traits and diseases) 
We used Gene Ontology data to identify any enrichment among the 109 pleiotropic 
SNPs for brain-related traits. Gene sets for which significant enrichment was identified 
are listed along with raw and adjusted p-values. 
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Figure S1. Hierarchical clustering of genetic architecture across eight 
neuropsychiatric disorders. (Related to Table S3) Hierarchical clustering revealed 
three sub-groups within the eight disorders. Results were very similar to those obtained 
using exploratory factor analysis and genomic structural equation modeling.  
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Figure S2. P-M plots for top 146 loci. (Related to Figure 3 and Table S5) M-values 
were generated for each locus for each disorder and indicate the presence or absence 
of a disorder-specific effect. M-values were plotted with the negative log odds of the 
corresponding p-values for each disorder for a given SNP; P-M plots were generated for 
each of the top 146 loci. Log odds ratios for the effect of the SNP on each disorder and 
a summary across disorders was also plotted. As expected, most of the top SNPs 
(109/146) were pleiotropic.  
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Figure S3. Statistical power and number of cross-disorder associations (Related 
to Table S4). Power to detect associations across pairs of disorders was plotted with 
the number of cross-disorder associations identified in the current meta-analysis. For 
each pair of disorders, power was estimated using the number of cases and heritability 
for each disorder, as well as the genetic correlation between the disorders. In general, 
as power increased, so did the number of SNPs identified. 
 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/528117doi: bioRxiv preprint first posted online Jan. 26, 2019; 
SCZ/BIP
SCZ/MDD
SCZ/AUT
SCZ/ADD
SCZ/TS
SCZ/ANO
SCZ/OCD
BIP/MDD
BIP/AUT
BIP/ADDBIP/TS
BIP/ANO
BIP/OCD
MDD/AUT
MDD/ADD
MDD/TS
MDD/ANOMDD/OCD
AUT/ADD
AUT/TS
AUT/ANOAUT/OCDADD/TS
ADD/ANOADD OCDTS/ANOTS/OCD
ANO/OCD
0
20
40
60
80
0 2500 5000 7500
sqrt(N1 * h2_1 * N2 * h2_2 * rg * rg)
# 
of
 c
ro
ss
-d
is
or
de
r a
ss
oc
ia
tio
ns
Statistical Power and Numbers of Cross-Disorder Associations
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/528117doi: bioRxiv preprint first posted online Jan. 26, 2019; 
Figure S4. Gene expression of top loci across development. (Related to Figure 3) 
Gene expression trajectories from a transcriptome atlas of post-mortem brain tissue 
across development are plotted for four top loci, DCC, RBFOX1, NOX4 and BRAF in six 
different brain tissue types. AMY = amygdala; MD = mediodorsal nucleus of the 
thalamus; CBC = cerebellar cortex; NCX = neocortex; HIP = hippocampus; STR = 
striatum.  
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Figure S5. Gene expression in the brain for pleiotropic and non-pleiotropic loci. 
(Related to Figure 5) Average normalized gene expression in fetal and adult post-
mortem brain tissue for pleiotropic (109) and non-pleiotropic (37) loci were plotted. 
Disorder-specific and pleiotropic risk loci showed a similar level of gene expression in 
prenatal and postnatal development after multiple testing correction (t-test p > 0.025).  
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